title: Evaluation of quinapril on regional blood flow and cardiac function in patients with congestive heart failure.
abstract: Quinapril, a nonsulfhydryl ACE inhibitor, was evaluated in ten New York Heart Association (NYHA) functional class (FC) II-III CHF patients to determine its effects on regional blood flow [effective renal plasma flow (ERPF), renal blood flow (RBF), renal vascular resistance (RVR), hepatic blood flow (HBF), hepatic vascular resistance (HVR), segmental limb pressure (SLP), creatinine clearance (CRCL)] and cardiac function [left ventricular ejection fraction (LVEF)]. Previous vasodilator therapy was withdrawn 2 weeks before baseline measurements. Stable regimens of digoxin and diuretics were continued throughout the study. ERPF was assessed using p-aminohippurate (PAH), HBF by indocyanine green (ICG) clearance, and LVEF by radionuclide scintography. Segmental limb pressures were measured by Doppler flow detection. Measurements were performed at baseline (B) and after 4 weeks of quinapril therapy (10 mg BID). Quinapril increased renal (P less than 0.05) and hepatic blood flow (P = 0.06) and significantly reduced renal and hepatic vascular resistance. Glomerular filtration rate and left ventricular ejection fraction were unchanged. Mean arterial pressure and brachial segmental pressures decreased without change in heart rate. Noninvasive cardiovascular assessments indicate that quinapril improves regional blood flow while exhibiting no change in left ventricular ejection fraction, in patients with NYHA FC II-III CHF.
authors.affiliation: Division of Cardiology, University Hospitals of Cleveland, Case Western Reserve University School of Medicine, Ohio.
authors.forename: M A
authors.initials: MA
authors.lastname: Munger
authors.forename: M
authors.initials: M
authors.lastname: Chance
authors.forename: R
authors.initials: R
authors.lastname: Nair
authors.forename: A W
authors.initials: AW
authors.lastname: Prescott
authors.forename: A R
authors.initials: AR
authors.lastname: Nara
authors.forename: M S
authors.initials: MS
authors.lastname: Simonson
authors.forename: J A
authors.initials: JA
authors.lastname: Green
authors.forename: E L
authors.initials: EL
authors.lastname: Posvar
mesh_terms: D000959:Antihypertensive Agents / Q000008:administration & dosage / Q000494:pharmacology*; D001794:Blood Pressure / Q000187:drug effects; D005260:Female; D005919:Glomerular Filtration Rate / Q000187:drug effects; D006333:Heart Failure / Q000188:drug therapy / Q000503:physiopathology*; D006439:Hemodynamics / Q000187:drug effects* / Q000502:physiology; D006801:Humans; D007546:Isoquinolines / Q000008:administration & dosage / Q000494:pharmacology*; D008102:Liver Circulation / Q000187:drug effects; D008297:Male; D000077583:Quinapril; D012039:Regional Blood Flow / Q000187:drug effects; D012079:Renal Circulation / Q000187:drug effects; D013318:Stroke Volume / Q000187:drug effects; D044005:Tetrahydroisoquinolines; D016277:Ventricular Function, Left / Q000187:drug effects
chemical_list: D000959:Antihypertensive Agents; D007546:Isoquinolines; D044005:Tetrahydroisoquinolines; D000077583:Quinapril